Skip to main content
Erschienen in: Tumor Biology 8/2015

01.08.2015 | Research Article

Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

verfasst von: Chuan Chen, Dong-Ping Chen, Yan-Yan Gu, Liang-Hao Hu, Dan Wang, Jin-Huan Lin, Zhao-Shen Li, Jing Xu, Ge Wang

Erschienen in: Tumor Biology | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Vascular invasion is one of the most important prognostic factors for patients with hepatocellular carcinoma (HCC). The objective of the current, retrospective study was to determine the associations of ascites and hepatitis B viral factors (HBeAg and anti-HBe status and HBV DNA levels), as well as tumor-related factors (size, tumor number, grade, and location) with micro- or macroscopic vascular invasion in patients with HCC that developed as a result of hepatitis B virus (HBV)-related cirrhosis. A total of 336 consecutive patients were included. Potential factors associated with micro- or macroscopic vascular invasion were analyzed by logistic regression. Ascites were more commonly detected in patients with micro- or macroscopic vascular invasion, and the presence of ascites was independently associated with vascular invasion. Among patients with mild-to-moderate or severe ascites, the odds ratio for macroscopic vascular invasion was 4.83 (95 % confidence interval [CI] 2.29–10.16) and 11.87 (95 % CI 4.53–31.07), respectively. Similarly, the presence of ascites was associated with microscopic vascular invasion (OR 5.00; 95 % CI 1.23–20.31). In contrast, hepatitis B viral factors were not significantly associated with vascular invasion. The presence of ascites was associated with vascular invasion in patients with HBV-related cirrhotic HCC. Thus, patients with ascites, vascular invasion should be considered and more frequent surveillance should be performed after curative treatment.
Literatur
5.
Zurück zum Zitat Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.CrossRefPubMed Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.CrossRefPubMed
7.
Zurück zum Zitat Ishikawa T, Ichida T, Yamagiwa S, Sugahara S, Uehara K, Okoshi S, et al. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol. 2001;16:1274–81.CrossRefPubMed Ishikawa T, Ichida T, Yamagiwa S, Sugahara S, Uehara K, Okoshi S, et al. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol. 2001;16:1274–81.CrossRefPubMed
10.
Zurück zum Zitat Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6. doi:10.1053/jhep.2001.23561.CrossRefPubMed Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6. doi:10.​1053/​jhep.​2001.​23561.CrossRefPubMed
12.
Zurück zum Zitat Hsieh CH, Wei CK, Yin WY, Chang CM, Tsai SJ, Wang LY, et al. Vascular invasion affects survival in early hepatocellular carcinoma. Mol Clin Oncol. 2015;3:252–6. doi:10.3892/mco.2014.420.PubMed Hsieh CH, Wei CK, Yin WY, Chang CM, Tsai SJ, Wang LY, et al. Vascular invasion affects survival in early hepatocellular carcinoma. Mol Clin Oncol. 2015;3:252–6. doi:10.​3892/​mco.​2014.​420.PubMed
13.
Zurück zum Zitat Sumie S, Nakashima O, Okuda K, Kuromatsu R, Kawaguchi A, Nakano M, et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;21:1002–9. doi:10.1245/s10434-013-3376-9.CrossRefPubMed Sumie S, Nakashima O, Okuda K, Kuromatsu R, Kawaguchi A, Nakano M, et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;21:1002–9. doi:10.​1245/​s10434-013-3376-9.CrossRefPubMed
14.
Zurück zum Zitat Figueras J, Ibanez L, Ramos E, Jaurrieta E, Ortiz-de-Urbina J, Pardo F, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl. 2001;7:877–83. doi:10.1053/jlts.2001.27856.CrossRefPubMed Figueras J, Ibanez L, Ramos E, Jaurrieta E, Ortiz-de-Urbina J, Pardo F, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl. 2001;7:877–83. doi:10.​1053/​jlts.​2001.​27856.CrossRefPubMed
15.
Zurück zum Zitat Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11:1086–92. doi:10.1002/lt.20472.CrossRefPubMed Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11:1086–92. doi:10.​1002/​lt.​20472.CrossRefPubMed
16.
Zurück zum Zitat Shirabe K, Toshima T, Kimura K, Yamashita Y, Ikeda T, Ikegami T, et al. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int. 2014;34:937–41. doi:10.1111/liv.12459.CrossRefPubMed Shirabe K, Toshima T, Kimura K, Yamashita Y, Ikeda T, Ikegami T, et al. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int. 2014;34:937–41. doi:10.​1111/​liv.​12459.CrossRefPubMed
18.
Zurück zum Zitat Kim BK, Han KH, Park YN, Park MS, Kim KS, Choi JS, et al. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol. 2008;97:246–52. doi:10.1002/jso.20953.CrossRefPubMed Kim BK, Han KH, Park YN, Park MS, Kim KS, Choi JS, et al. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol. 2008;97:246–52. doi:10.​1002/​jso.​20953.CrossRefPubMed
19.
Zurück zum Zitat Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg. 2002;6:224–32. discussion 232.CrossRefPubMed Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg. 2002;6:224–32. discussion 232.CrossRefPubMed
20.
Zurück zum Zitat Hsu C-Y, Lee Y-H, Huang Y-H, Hsia C-Y, Su C-W, Lin H-C, et al. Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatol Int. 2013;7:188–98. doi:10.1007/s12072-011-9338-z.CrossRefPubMed Hsu C-Y, Lee Y-H, Huang Y-H, Hsia C-Y, Su C-W, Lin H-C, et al. Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatol Int. 2013;7:188–98. doi:10.​1007/​s12072-011-9338-z.CrossRefPubMed
21.
Zurück zum Zitat Chen LP, Li C, Wang C, Wen TF, Yan LN, Li B. Risk factors of ascites after hepatectomy for patients with hepatocellular carcinoma and hepatitis B virus-associated cirrhosis. Hepatogastroenterology. 2012;59:292–5. doi:10.5754/hge11399.CrossRefPubMed Chen LP, Li C, Wang C, Wen TF, Yan LN, Li B. Risk factors of ascites after hepatectomy for patients with hepatocellular carcinoma and hepatitis B virus-associated cirrhosis. Hepatogastroenterology. 2012;59:292–5. doi:10.​5754/​hge11399.CrossRefPubMed
23.
Zurück zum Zitat Lencioni R, Bartolozzi C, Caramella D, Paolicchi A, Carrai M, Maltinti G, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Cancer. 1995;76:1737–46.CrossRefPubMed Lencioni R, Bartolozzi C, Caramella D, Paolicchi A, Carrai M, Maltinti G, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Cancer. 1995;76:1737–46.CrossRefPubMed
24.
Zurück zum Zitat Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child’s grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol. 1999;28:334–40.CrossRefPubMed Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child’s grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol. 1999;28:334–40.CrossRefPubMed
27.
Zurück zum Zitat Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47:684–90. doi:10.1016/j.jhep.2007.06.019.CrossRefPubMed Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47:684–90. doi:10.​1016/​j.​jhep.​2007.​06.​019.CrossRefPubMed
29.
Zurück zum Zitat Jang JW, Choi JY, Bae SH, Yoon SK, Woo HY, Chang UI, et al. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence. Cancer. 2007;110:1760–7. doi:10.1002/cncr.22984.CrossRefPubMed Jang JW, Choi JY, Bae SH, Yoon SK, Woo HY, Chang UI, et al. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence. Cancer. 2007;110:1760–7. doi:10.​1002/​cncr.​22984.CrossRefPubMed
30.
Zurück zum Zitat Urata Y, Kubo S, Takemura S, Uenishi T, Kodai S, Shinkawa H, et al. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012;19:685–96. doi:10.1007/s00534-011-0489-z.CrossRefPubMed Urata Y, Kubo S, Takemura S, Uenishi T, Kodai S, Shinkawa H, et al. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012;19:685–96. doi:10.​1007/​s00534-011-0489-z.CrossRefPubMed
31.
Zurück zum Zitat DiMaio CJ, Krishnan S, Roayaie S. EUS-guided ethanol ablation for management of metastatic hepatocellular carcinoma. J Interv Gastroenterol. 2014;4(1):13–14. doi:10.7178/jig.138. DiMaio CJ, Krishnan S, Roayaie S. EUS-guided ethanol ablation for management of metastatic hepatocellular carcinoma. J Interv Gastroenterol. 2014;4(1):13–14. doi:10.​7178/​jig.​138.
33.
Zurück zum Zitat Verslype C, Rosmorduc O, Rougier P, Group EGW. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii41–8. doi:10.1093/annonc/mds225.CrossRefPubMed Verslype C, Rosmorduc O, Rougier P, Group EGW. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii41–8. doi:10.​1093/​annonc/​mds225.CrossRefPubMed
36.
Zurück zum Zitat Huang C, Sheng Y, Jia J, Chen L. Identification of melanoma biomarkers based on network modules by integrating the human signaling network with microarrays. J Cancer Res Ther. 2014;10 Suppl:C114–124. doi:10.4103/0973-1482.145816. Huang C, Sheng Y, Jia J, Chen L. Identification of melanoma biomarkers based on network modules by integrating the human signaling network with microarrays. J Cancer Res Ther. 2014;10 Suppl:C114–124. doi:10.​4103/​0973-1482.​145816.
42.
Zurück zum Zitat Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8:765–74. doi:10.1053/jlts.2002.34892.CrossRefPubMed Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8:765–74. doi:10.​1053/​jlts.​2002.​34892.CrossRefPubMed
43.
Zurück zum Zitat You Z, Chen LP, Ye H. Predictors of microvascular invasion in patients with solitary small hepatitis B related hepatocellular carcinoma. Pak J Med Sci. 2014;30:331–4.CrossRefPubMedPubMedCentral You Z, Chen LP, Ye H. Predictors of microvascular invasion in patients with solitary small hepatitis B related hepatocellular carcinoma. Pak J Med Sci. 2014;30:331–4.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108–13. doi:10.1097/SLA.0b013e31821ad884.CrossRefPubMed Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108–13. doi:10.​1097/​SLA.​0b013e31821ad884​.CrossRefPubMed
46.
Zurück zum Zitat McHugh PP, Gilbert J, Vera S, Koch A, Ranjan D, Gedaly R. Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford). 2010;12:56–61. doi:10.1111/j.1477-2574.2009.00128.x.CrossRef McHugh PP, Gilbert J, Vera S, Koch A, Ranjan D, Gedaly R. Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford). 2010;12:56–61. doi:10.​1111/​j.​1477-2574.​2009.​00128.​x.CrossRef
48.
Zurück zum Zitat Nguyen VX, Nguyen CC, De Petris G, Sharma VK, Das A. Confocal endomicroscopy (CEM) improves efficiency of Barrett surveillance. J Interv Gastroenterol. 2012;2(2):61-65. doi:10.4161/jig.22175. Nguyen VX, Nguyen CC, De Petris G, Sharma VK, Das A. Confocal endomicroscopy (CEM) improves efficiency of Barrett surveillance. J Interv Gastroenterol. 2012;2(2):61-65. doi:10.​4161/​jig.​22175.
50.
Zurück zum Zitat Xu J, Shi J, Wang YP, Lin Y, Chen YX, Lu J, et al. Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis. Med Sci Monit. 2009;15:Cr274–9.PubMed Xu J, Shi J, Wang YP, Lin Y, Chen YX, Lu J, et al. Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis. Med Sci Monit. 2009;15:Cr274–9.PubMed
51.
Zurück zum Zitat Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:1756–61. doi:10.1111/jgh.12310.CrossRefPubMed Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:1756–61. doi:10.​1111/​jgh.​12310.CrossRefPubMed
52.
56.
Zurück zum Zitat Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep. 2003;10:89–95.PubMed Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep. 2003;10:89–95.PubMed
Metadaten
Titel
Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?
verfasst von
Chuan Chen
Dong-Ping Chen
Yan-Yan Gu
Liang-Hao Hu
Dan Wang
Jin-Huan Lin
Zhao-Shen Li
Jing Xu
Ge Wang
Publikationsdatum
01.08.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 8/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3311-8

Weitere Artikel der Ausgabe 8/2015

Tumor Biology 8/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.